Kornimate/medical-research-clean huggingface dataset:
nitrous oxide as treatment for major depression - a pilot study

Conditions: Depression; Major Depressive Disorder

Summary: major depressive disorder (mdd) is a global medical problem with significant shortcomings in current therapy. chief among these is the delay between initiation of pharmacologic therapy and clinical improvement in symptoms. recently ketamine, an ndma-receptor antagonist has been shown to rapidly and effectively reverse the symptoms of mdd. nitrous oxide, another nmda-receptor antagonist, may produce the same effect with a cleaner side-effect profile and perhaps without the need for intravenous access and anesthesia personnel. therefore, we propose conducting a pilot randomized placebo controlled double-blind crossover study in which patients will receive up to 50% nitrous oxide in oxygen or up to 50% oxygen in air for a period of one hour in addition to standard medical therapy. depression severity will be assessed by a blinded observer pre-treatment, 30 minutes and 2 hours post treatment using the hamilton depression rating scale.

we will study 20 patients with non-treatment resistant major depression and 20 patients with treatment-resistant major depression, defined as failure of at least 2 antidepressants in the current depressive episode and 3 lifetime medication failures.

Eligibility criteria:
inclusion criteria: 1. adults 18-65 years of age 2. major depressive disorder without psychosis with as determined by structured interview using the mini-international neuropsychiatric interview (mini). (baseline ) 3. hdrs-21 score of \>18 4. good command of the english language exclusion criteria: history of: 1. bipolar disorder 2. schizoprenia 3. schizoaffective disorder 4. obsessive-compulsive disorder, panic disorder 5. substance abuse or dependence (except for remote substance abuse or dependence with remission at least 1 year prior to the study and except for nicotine use disorders) 6. axis ii diagnoses that may interfere with the patient's ability to improve on nitrous oxide 7. acute medical illness that may pose subject at risk during nitrous oxide administration 8. active suicidal intention (inability to contract for safety) 9. active psychotic symptoms 10. patients with significant pulmonary disease and/or requiring supplemental oxygen 11. contraindication against the use of nitrous oxide: 1. pneumothorax 2. bowel obstruction 3. middle ear occlusion 4. elevated intracranial pressure 5. chronic cobalamin and/or folate deficiency treated with folic acid or vitamin b12 6. pregnant patients 7. breastfeeding women 12. previous administration of nmda-receptor antagonists (e.g., ketamine) within the last 3 months 13. current electro-convulsive therapy treatment 14. any active suicidal ideation, intention, or planning (clinical assessment of suicidality will be used)

Keywords: treatment
treatment of moderate fmr during avr

Conditions: Functional Mitral Regurgitation

Summary: debates exist on the treatment of moderate functional mitral regurgitation (fmr) in patients undergoing aortic valve replacement (avr) for aortic valve disease. this study aims to evaluate the left ventricular function, which was evaluated through global longitudinal strain, after isolated avr and avr + mitral valve repair (mvr) in this group of patients.


Eligibility criteria:
inclusion criteria: 1. patients who received avr (with or without concomitant mvr) from two center (fuwai yunnan cardiovascular hospital and fuwai hospital, chinese academy of medical sciences). 2. age more than 18 years. exclusion criteria: 1. those with a history of rheumatic valvular disease or infective endocarditis. 2. primary mitral valve lesions. 3. patients receiving mitral valve replacement. 4. patient who refuse to participate in this study, or cannot complete 6-month follow-up after surgery. 5. age \< 18 years.

Keywords: functional mitral regurgitation aortic valve replacement mitral valve repair
munich study for beer related ecg change workup

Conditions: Arrhythmias, Cardiac

Summary: the study aims to determine if acute recreational alcohol intake is associated with the occurence of ecg changes and arrhythmias.

both regular and acute excessive alcohol intake may deteriorate health. possible sequelae include cardiac arrhythmias. for acute alcohol intake in particular it is insufficiently understood to what extent cardiac arrhythmias and other ecg changes occur, if the occurence depends on alcohol levels, and if there is a cut off value for occurence. munich brew aims to help clarifying these questions. participants of munich brew are identified and invited as visitors of the munich octoberfest and similar events. participants need to be 18 years of age and over and need to declare theri will to participate. following enrollment, participants will answer astudy questionnaire and will subsequently undergo recording of a 30 sec smart phone based ecg. ultimately, the alcohol level is determined using a breath alcohol analyzer.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * informed conset signature exclusion criteria: * incapability of contracting according to german law (bgb §105, paragraph 2) * contraindications against ecg recording or alcohol breath test * denial of informed consent

Keywords: arrhythmia alcohol ecg
azithromycin versus doxycycline on restistin level in periodontitis patients with type 2 diabetes

Conditions: Periodontal Diseases; Type 2 Diabetes

Summary: the aim of this study is to evaluate the adjunctive effects of systemic antibiotics used in nonsurgical periodontal treatment (nspt), compared with nspt alone, on the periodontal clinical parameters and resistin level in diabetic patients with periodontitis, in order to identify which, one provides an additional effect to non-surgical periodontal therapy


Eligibility criteria:
inclusion criteria: patients were clinically diagnosed as having at least three site with cal ≥ 5mm; moderate to advanced chronic periodontitis according to the criteria of american academy of periodontology. * free from any other systemic conditions that affect the periodontium except for diabetes mellitus type ii. * no periodontal therapy, systemic antibiotics or non-steroidal anti-inflammatory agents during the preceding 6 months. * non-smokers. * non-pregnant. exclusion criteria: -
pharmacokinetic characterization of intramuscular olanzapine depot

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the goals of this study are to: determine the blood levels of intramuscular (im) olanzapine depot in patients at different points in time after an injection, and compare these levels to the amount of olanzapine in the blood of patients after treated by oral administration with zyprexa (olanzapine) tablets or by intramuscular administration with zyprexa intramuscular (olanzapine for injection).


Eligibility criteria:
inclusion criteria: * patients must have schizophrenia or schizoaffective disorders. * each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent. * patient must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry. * female patients must not be pregnant or breast-feeding. * patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia or schizoaffective disorder.
a commitment device for medication adherence among hiv patients

Conditions: Acquired Immunodeficiency Syndrome; HIV

Summary: we used a randomized trial design combined with a comparison to a non-randomized control group to study patients on appropriate antiretroviral therapy (art) having virologic failure within a publicly-funded hiv clinic serving atlanta, ga.

this study demonstrated the feasibility of using commitment contracts in hiv care. many previous interventions have produced statistically significant effects on art adherence that do not persist after the intervention ends. a notable feature of our study is that after the incentives for art adherence and provider visits were removed, participants who had been offered a commitment contract for art adherence were more likely to achieve virologic suppression relative to individuals who had been assigned a conditional cash transfer for provider visits and relative to individuals who had been assigned the standard of care, although the difference was only statistically significant in the latter comparison. there were differences in the prevalence of missing outcomes across groups, but these differences were not statistically significant for the unanticipated post-incentive visit and therefore were unlikely to be the explanation for the results. thus, financial rewards coupled with individual choice can increase engagement in healthy behaviors after incentives are removed.

Eligibility criteria:
inclusion criteria: * attended the grady health system infectious disease program (idp) * most recent hiv-1 plasma rna viral load (pvl) \> 200 copies/ml; this value must have been measured within the prior 18 months and at least 6 months after starting the current art regimen * english-speaking exclusion criteria: * using pillboxes * were planning to relocate * were enrolled in another trial

Keywords: acquired immunodeficiency syndrome hiv commitment financial incentives
study of cannabidiol for drug-resistant epilepsies

Conditions: Drug Resistant Epilepsy

Summary: the purpose of this study is to determine if cannabidiol is safe and effective at different doses as an additional treatment for pediatric drug-resistant epilepsy. pure cannabidiol has potentially therapeutic properties, such as anti-convulsant effects, that may reduce seizure frequency. there are only a few open label studies that have demonstrated the safety and tolerance of cannabiodiol in both adult and pediatric epileptic populations--these studies were performed either retrospectively or with varying cannabidiol preparations. there are no well-documented studies and completely analyzed data for pediatric epileptic patients.


Eligibility criteria:
inclusion criteria: 1. ages between 1 year old and 20 years old, male or female at the first visit, week -4 (at time informed consent form is signed) 2. documentation of a diagnosis of drug-resistant epilepsy as proven by and documented with medical records and/or the following clinical features (must have all 3 of the following): 1. failure to control seizures despite appropriate trial of 3 or more aeds at therapeutic doses 2. an intractable childhood epilepsy including, dravet syndrome or lennox-gastaut syndrome 3. must report at least 3 countable (non-countable seizures includes absence and myoclonic) seizures per month 3. between 1-3 baseline aeds . vagus nerve stimulator (vns), ketogenic diet, and modified atkins diet do not count towards this limit. 4. vns must be on stable settings for a minimum of 3 months. 5. if on the ketogenic diet, must be on stable ratio for a minimum of 3 months. exclusion criteria: 1. epilepsies associated with neurodegenerative diseases, including neuronal ceroidolipofuscinosis, progressive myoclonus epilepsies, rasmussen encephalitis, and tumors 2. epilepsies associated with an inborn error of metabolism, including mitochondrial disorders 3. felbatol initiated within the past 12 months 4. use of any cannabis-related product (including hemp oil) in the past 12 months as assessed by parental questioning. 5. laboratory values on comprehensive metabolic panel (cmp) and complete blood count (cbc) testing that are class 3 or higher according to the ctcae v4.0. 6. positive pregnancy test.
thermotherapy of buruli ulcer at community level in the health district of akonolinga

Conditions: Buruli Ulcer

Summary: the project rolls out combined innovative low-tech thermotherapy of buruli ulcer (bu) with heat packs and who recommended wound management in a bu endemic district of cameroon.

the project translates available clinical research findings at the secondary health care level into clinical practice at the primary health care and community level. the string of previous work from the development of the bu thermotherapy-wound management-package to the proof of its efficacy provides all necessary procedures, tools and documents to immediately proceed into practical and integrated community application. main objective: to determine in patients with early bu lesions the effectiveness and acceptability of thermotherapy treatment at health post and community level. specific objectives: 1. to monitor and evaluate clinical and biological responses to thermotherapy in patients receiving up to 8 weeks of thermotherapy 2. to assess within 6 months after completion of heat treatment wound closure ("primary cure") and/or absence of bu specific features in included patients according to who healing criteria 3. to measure the bu recurrence rate in included patient within 12 months after completion of heat treatment' ("definite cure"). 4. to assess the compliance rate of included patients 5. to assess the withdrawal rate of included patients 6. to assess the ability and comfort of health personnel to use the thermotherapy device

Eligibility criteria:
inclusion criteria: * clinically diagnosed bu patients with a single who category i and ii lesion exclusion criteria: - inappropriate lesion size (category iii patients), location and patients with multiple lesions
blood pressure in adolescents with preclampsia and eclampsia.

Conditions: Adolescent Pregnancy; Preeclampsia and Eclampsia

Summary: levels of blood pressure in adolescents with preeclampsia and eclampsia: multicenter case-control study (latin america). maternities in latin america: two hospitals in panama, one hospital in mexico, one hospital in el salvador, one hospital in guatemala, two hospitals in honduras, one hospital in colombia, two hospitals in peru and two hospitals in bolivia. the objective is to evaluate the basal levels of blood pressure during pregnancy and determine if there is any increase that is associated with the development of preeclampsia and eclampsia without reaching the known values of 140/90 mm hg. the sample is 1050: (350 cases and 700 controls).

levels of blood pressure in adolescents with preeclampsia and eclampsia: cases and controls study. it is unknown whether the blood pressure levels used for the diagnosis of preeclampsia have the same impact in adolescents as in older women, however for the diagnosis of preeclampsia and severe hypertension the same criteria of hypertension are used regardless of age maternal. it is necessary to do research to determine the values of blood pressure with which adolescents convulse and also to validate if slight increases in baseline blood pressure in adolescents are associated with prediction of preeclampsia and eclampsia. unfortunately, 85% of teenage pregnancies occur in non-industrialized countries such as those in latin america, and it is estimated that 25% of maternal deaths occur in adolescents cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy. controls are patients with the same criteria but without hypertension during this pregnancy. the statistical analyzes are based on comparing blood pressure levels between the two groups, in addition blood pressure levels like 30/15 on the systolic and diastolic basal levels will be created and compared between the two groups, especially when it is not possible to have 140 / 90 mm hg.

Eligibility criteria:
inclusion criteria: * criteria for inclusion cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that has 24 and more weeks of pregnancy with prenatal control started before 20 weeks of age. pregnancy. that you get the data of the termination of your pregnancy. exclusion criteria: * patients with pregnancy that starts before 19 years of age that does not develop preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that has 24 and more weeks of pregnancy with prenatal control started before 20 weeks of pregnancy. that you get the data of the termination of your pregnancy.
zero-fluoroscopic navigation versus conventional fluoroscopic navigation for single-chamber pacemaker implantation

Conditions: Sick Sinus Syndrome; Complete Atrioventricular Block; High Degree Second Degree Atrioventricular Block; Bradycardia

Summary: this study is intended to compare the feasibility, safety and efficacy of ensite-navx zero-fluoroscopic navigation system to conventional fluoroscopic x-ray approach as to performing single-chamber pacemaker implantation.

permanent pacemaker is a well-established treatment to treat patients with a wide range of heart rhythm disturbances. fluoroscopy is the imaging modality routinely used for cardiac device implantation and electrophysiological procedures.due to the rising concern regarding the harmful effects of radiation exposure to both the patients and operation staffs, novel 3d mapping systems have been developed and implemented in electrophysiological procedure for the navigation of catheters inside the heart chambers. ensite navx system can be used for cardiac imaging as a reliable and safe zero-fluoroscopy approach for implantation of single- or dual-chamber permanent pacemaker in patients. our method offered a choice for some special population of patient in whom radiation exposure need to be avoided or in the extreme circumstances when the x-ray machine is out-of-order.

Eligibility criteria:
inclusion criteria: * sick sinus syndrome * complete atrioventricular block * high degree second degree atrioventricular block * bradycardia exclusion criteria: * pacemaker replacement * severe structural l cardiac malformations * severe cardiac enlargement * venous malformations

Keywords: fluoroscopy pacemaker three dimensional radiation imaging
evaluation of tissue glue on picc and midline catheters insertion sites

Conditions: Adult Patients With Mid-term or Long-term Venous Access

Summary: the study will evaluate a new type of cyanoacrylate tissue glue secure portiv on the insertion site of the picc (peripherally inserted central catheter) or midline catheters. fixation of the catheter with the tissue glue should prevent incidents of mechanical and infective phlebitis as well as external migrations of the catheters.

in the study, 125 subjects will receive the new tissue glue secure portiv and 125 subjects will be provided standard care. the tissue glue will be applied immediately after insertion. evaluation and re-evaluation of the site will be done on the first and seventh day after insertion using vip and clisa (central-line insertion site assessment) scale and on the seventh day with taking a swab from the insertion site; the external length will be measured on the first and the seventh day, in order to observe the migration or not. the goal of the study is to evaluate the benefits of the cyanoacrylate tissue glue secure portiv in the prevention of mechanical and infective phlebitis and external migration of the catheter.

Eligibility criteria:
inclusion criteria: * 18 years of age * need of long-term venous access * consent with participation in the study exclusion criteria: * pediatric population * not signing the informed consent form

Keywords: peripherally inserted central catheter midline cyanoacrylate tissue glue tissue glue phlebitis catheter migration
a study of laparoscopic right hemicolectomy using the caudal-to-cranial approach

Conditions: Ascending Colon Cancer; Ileocaecal Valve Carcinoma; Cancer Flexure Hepatic; Adenocarcinoma of Hepatic Flexure (Diagnosis)

Summary: to investigate the clinical application value of laparoscopic radical right hemicolectomy using the caudal-to-cranial approach versus the medial-to-lateral approach by prospective randomized controlled clinical study.

to compare the caudal-to-cranial approach with the medial-to-lateral approach in laparoscopic right hemicolectomy for the advance right colon cancer. a prospective randomized controlled trial will be performed in the gi department,the guangdong provincial hospital of chinese medicine from october 2016 to october 2024.the sample size，150 cases with advanced right colon cancer, will be needed after calculated by the statistics .the 150 cases will be randomly divided into two groups: laparoscopic radical right hemicolectomy using the caudal-to-cranial(ctc) approach(groupctc) and laparoscopic radical right hemicolectomy using the medial-to-lateral(mtl) approach (groupmtl). primary outcomes are the operative time，the secondary outcomes are the total blood loss,the number of lymph nodes dissected,the average time of ground activities,the time to first flatus,the hospital stay,the intra-operative complication and the post-operative complication，and others' outcomes are the disease-free survival rate(dfs) at 3 years and 5 years,the overall survival rate（os）at 3 years and 5 years.the data in two groups will be compared.

Eligibility criteria:
inclusion criteria: 1. the age limits is 18-80 years old; 2. the clinical staging was ii,iii carcinoma of right colon，located in right-sided colon; 3. the preoperative imaging confirmed that the tumor did not involve adjacent organs; 4. american society of anesthesiologists (asa) score less than or equal to level iii; 5. criteria of performance status karnofsky is greater than or equal to 60. exclusion criteria: 1. the patients' age limits is less than 18 years old, or more than 80 years old 2. the preoperative imaging confirmed that the tumor involve adjacent organs; 3. the tumor have been finding distant metastases; 4. american society of anesthesiologists (asa) score more than 3; 5. criteria of performance status karnofsky is lower than 60; 6. it is the carcinoma of right colon with multiple colonic polyps disease; 7. there is a laparoscopic surgery contraindications.

Keywords: laparoscopic right hemicolectomy caudal-to-cranial approach
rapid versus prolonged inpatient up-titration of captopril

Conditions: Heart Disease

Summary: the primary objective of this study is to establish a safe and effective method of up-titration of captopril for hospital inpatients.

angiotensin converting enzyme inhibitors (acei) are one of the most frequently prescribed pediatric cardiac medication and overall their safety in children is widely accepted. pediatric formulary recommendations for acei suggest starting with a low initial dose (0.1 mg/kg), to avoid hypotension, and up-titration for a maintenance dose. however, side ranges are quoted for maintenance doses and no guidance is given as to the best method of up-titration, the physician is left uncertain of the optimal dose and how best to achieve it. the ultimate goal of this study is to be in a position to provide physicians caring for children with heart disease information about how to safely up-titrate this widely used medication, and by doing so to improve dosing in the wider pediatric population.

Eligibility criteria:
inclusion criteria: * pediatric cardiology in-patients at the hospital for sick children * primary physician has decided to commence acei (the division has agreed that our institutional choice will be to start patients on captopril and up-titrate to optimal dose before converting to other acei) * patients who have been initiated on captopril within the prior 24 hours, but have not yet started up-titration, will be eligible to be randomized exclusion criteria: * known sensitivity to acei * infants on the neonatal intensive care unit * treatment with any acei for more than 24 hours within the preceding 6 months * age \> 18 years

Keywords: up-titration captopril pediatric cardiac patients